UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Annals of oncology, 2005-10, Vol.16 (10), p.1688-1694

2005

Volltextzugriff (PDF)

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Volltextzugriff (PDF)

Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report

Current oncology (Toronto), 2020-04, Vol.27 (2), p.71-74

2020

Volltextzugriff (PDF)

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors

Annals of oncology, 2017-04, Vol.28 (4), p.702-710

2017

Volltextzugriff (PDF)

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2017-06, Vol.35 (3), p.324-333

2017

Volltextzugriff (PDF)

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

British journal of cancer, 2013-08, Vol.109 (4), p.943-949

2013

Volltextzugriff (PDF)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

British journal of cancer, 2006-11, Vol.95 (9), p.1148-1154

2006

Volltextzugriff (PDF)

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

British journal of cancer, 2014-12, Vol.111 (12), p.2262-2267

2014

Volltextzugriff (PDF)

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Gynecologic oncology, 2015-07, Vol.138 (1), p.55-61

2015

Volltextzugriff (PDF)

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Annals of oncology, 2011-02, Vol.22 (2), p.335-340

2011

Volltextzugriff (PDF)

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

Annals of oncology, 2006-02, Vol.17 (2), p.334-340

2006

Volltextzugriff (PDF)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

British journal of cancer, 2011-03, Vol.104 (5), p.756-762

2011

Volltextzugriff (PDF)

Optimal chemotherapy treatment for women with recurrent ovarian cancer

Current oncology (Toronto), 2007-10, Vol.14 (5), p.195-208

2007

Volltextzugriff (PDF)

Telomerase Activity in Human Ovarian Carcinoma

Proceedings of the National Academy of Sciences - PNAS, 1994-04, Vol.91 (8), p.2900-2904

1994

Volltextzugriff (PDF)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

British journal of cancer, 2011-09, Vol.105 (7), p.884-889

2011

Volltextzugriff (PDF)

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

European journal of cancer (1990), 2006-03, Vol.42 (4), p.548-556

2006

Volltextzugriff (PDF)

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)

Gynecologic oncology, 2010-09, Vol.118 (3), p.308-312

2010

Volltextzugriff (PDF)

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

Gynecologic oncology, 2006-08, Vol.102 (2), p.300-308

2006

Volltextzugriff (PDF)

Telomerase activity associated with acquisition of malignancy in human colorectal cancer

Cancer research (Chicago, Ill.), 1995-06, Vol.55 (12), p.2533-2536

1995

Volltextzugriff (PDF)

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Gynecologic oncology, 2012-04, Vol.125 (1), p.136-140

2012

Volltextzugriff (PDF)

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Annals of oncology, 2018-10, Vol.29, p.viii340-viii340

2018

Volltextzugriff (PDF)

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2017-06, Vol.35 (3), p.397-397

2017

Volltextzugriff (PDF)

Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

European journal of cancer (1990), 2016-12, Vol.69, p.S97-S98

2016

Volltextzugriff (PDF)

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

Current oncology (Toronto), 2015-06, Vol.22 (3), p.211-219

2015

Volltextzugriff (PDF)

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Annals of oncology, 2012-01, Vol.23 (1), p.238-244

2012

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(200)

Publikationsform

Sprache

Englisch
(203)
Deutsch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Humans
(86)
Life Sciences & Biomedicine
(84)
Female
(74)
Oncology
(65)
Middle Aged
(47)
Aged
(45)
Biological And Medical Sciences
(42)
Adult
(41)
Medical Sciences
(38)
Male
(36)
Tumors
(28)
Ovarian Cancer
(26)
Chemotherapy
(22)
Neoplasms - Drug Therapy
(18)
Pharmacology. Drug Treatments
(18)
Ovarian Neoplasms - Drug Therapy
(17)
Antineoplastic Agents - Adverse Effects
(16)
Antineoplastic Agents - Therapeutic Use
(16)
Antineoplastic Agents
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

Optimal chemotherapy treatment for women with recurrent ovarian cancer

Telomerase Activity in Human Ovarian Carcinoma

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

Telomerase activity associated with acquisition of malignancy in human colorectal cancer

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Suchergebnisse filtern